GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » EV-to-EBITDA

DexTech Medical AB (XSAT:DEX) EV-to-EBITDA : -17.67 (As of Sep. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DexTech Medical AB's enterprise value is kr65.79 Mil. DexTech Medical AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-3.72 Mil. Therefore, DexTech Medical AB's EV-to-EBITDA for today is -17.67.

The historical rank and industry rank for DexTech Medical AB's EV-to-EBITDA or its related term are showing as below:

XSAT:DEX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -232.58   Med: -59.04   Max: -3.65
Current: -17.67

During the past 11 years, the highest EV-to-EBITDA of DexTech Medical AB was -3.65. The lowest was -232.58. And the median was -59.04.

XSAT:DEX's EV-to-EBITDA is ranked worse than
100% of 459 companies
in the Biotechnology industry
Industry Median: 8.73 vs XSAT:DEX: -17.67

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-22), DexTech Medical AB's stock price is kr4.70. DexTech Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.250. Therefore, DexTech Medical AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


DexTech Medical AB EV-to-EBITDA Historical Data

The historical data trend for DexTech Medical AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexTech Medical AB EV-to-EBITDA Chart

DexTech Medical AB Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -861.31 -345.74 -269.23 -23.93 -30.91

DexTech Medical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.83 -30.91 -14.81 -13.08 -23.92

Competitive Comparison of DexTech Medical AB's EV-to-EBITDA

For the Biotechnology subindustry, DexTech Medical AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's EV-to-EBITDA falls into.



DexTech Medical AB EV-to-EBITDA Calculation

DexTech Medical AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=65.793/-3.724
=-17.67

DexTech Medical AB's current Enterprise Value is kr65.79 Mil.
DexTech Medical AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DexTech Medical AB  (XSAT:DEX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

DexTech Medical AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.70/-0.250
=At Loss

DexTech Medical AB's share price for today is kr4.70.
DexTech Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.250.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


DexTech Medical AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DexTech Medical AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


DexTech Medical AB Business Description

Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a strong clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.